Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Strata Skin Sciences ( (SSKN) ) is now available.
On August 13, 2025, STRATA Skin Sciences reported its financial results for the second quarter ending June 30, 2025. The company highlighted significant developments, including the historic expansion of CPT codes for reimbursement, which could potentially triple the covered patient population in the US. Despite a 9% decrease in revenue compared to the previous year, STRATA is optimistic about its growth strategy, leveraging new reimbursement codes and expanding its patient pool. The company also reported a net loss of $2.5 million for the quarter, attributing some challenges to the seasonality of its business.
The most recent analyst rating on (SSKN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.
Spark’s Take on SSKN Stock
According to Spark, TipRanks’ AI Analyst, SSKN is a Neutral.
Strata Skin Sciences faces significant financial and technical challenges, with ongoing losses and bearish stock trends. However, positive developments in corporate events and strategic growth initiatives provide some optimism. The company’s ability to improve its financial performance and capitalize on recent strategic initiatives will be crucial for future stock performance.
To see Spark’s full report on SSKN stock, click here.
More about Strata Skin Sciences
STRATA Skin Sciences, Inc. is a medical technology company focused on developing, commercializing, and marketing innovative products for treating dermatologic conditions. The company is known for its XTRAC Excimer laser treatment and operates within the dermatology industry, targeting inflammatory and auto-immune skin diseases.
Average Trading Volume: 24,333
Technical Sentiment Signal: Sell
Current Market Cap: $7.55M
See more insights into SSKN stock on TipRanks’ Stock Analysis page.